Printer Friendly

IDSMB gives positive review for Neovacs' Phase IIb clinical trial of IFNalpha Kinoid in lupus.

M2 EQUITYBITES-July 11, 2017-IDSMB gives positive review for Neovacs' Phase IIb clinical trial of IFNalpha Kinoid in lupus


Neovacs SA (EPA: ALNEV) has received a positive data review from the Independent Data and Safety Monitoring Board (IDSMB) for the ongoing Phase IIb clinical trial of IFNalpha Kinoid in lupus, the French biotech company announced on Tuesday.

In its review -- the third IDSMB data review of the ongoing Phase IIb clinical trial -- the board looked at cumulative data, focusing on the safety data. The board told the company that no safety concerns were identified and it recommended continuing the study without any modifications.

The Phase IIb trial is a randomised, placebo-controlled, multicentre study (IFN-K-002) in systematic lupus erythematosus (LES). It is now fully enrolled, with 178 participants randomised to receive either injection of the IFNalpha Kinoid vaccine or placebo.

The trial's objective is to evaluate the biological and clinical efficacy of IFNalpha Kinoid, the company's most advanced product, in patients with moderate to severe lupus.

The ongoing trial is taking place in 21 countries across Europe, the US, Latin America, Asia and North Africa.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 11, 2017
Previous Article:SSM Holding commences production of 204 cooperative apartments after high sales pace in Kosmopoliten project.
Next Article:Vostok New Ventures Ltd reports on SDR repurchases.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters